SG11202007180QA - Fap inhibitor - Google Patents
Fap inhibitorInfo
- Publication number
- SG11202007180QA SG11202007180QA SG11202007180QA SG11202007180QA SG11202007180QA SG 11202007180Q A SG11202007180Q A SG 11202007180QA SG 11202007180Q A SG11202007180Q A SG 11202007180QA SG 11202007180Q A SG11202007180Q A SG 11202007180QA SG 11202007180Q A SG11202007180Q A SG 11202007180QA
- Authority
- SG
- Singapore
- Prior art keywords
- fap inhibitor
- fap
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155419 | 2018-02-06 | ||
| EP18155420 | 2018-02-06 | ||
| EP18199641 | 2018-10-10 | ||
| PCT/EP2019/052952 WO2019154886A1 (en) | 2018-02-06 | 2019-02-06 | Fap inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007180QA true SG11202007180QA (en) | 2020-08-28 |
Family
ID=67548792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007180QA SG11202007180QA (en) | 2018-02-06 | 2019-02-06 | Fap inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210038749A1 (en) |
| EP (1) | EP3749663A1 (en) |
| JP (1) | JP2021512949A (en) |
| KR (1) | KR20200123148A (en) |
| CN (1) | CN111699181A (en) |
| AU (2) | AU2019219057B2 (en) |
| BR (1) | BR112020015985A2 (en) |
| CA (1) | CA3088326A1 (en) |
| CL (1) | CL2020002026A1 (en) |
| CO (1) | CO2020009625A2 (en) |
| IL (1) | IL276594B2 (en) |
| MX (1) | MX2020008271A (en) |
| SG (1) | SG11202007180QA (en) |
| WO (1) | WO2019154886A1 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020004807A (en) | 2017-10-23 | 2020-10-05 | Univ Johns Hopkins | Imaging and radiotherapeutics agents targeting fibroblast-activation protein-¿ (fap-¿). |
| IL275333B2 (en) | 2017-12-15 | 2023-09-01 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| DE102018126558A1 (en) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Marking precursor with square acid coupling |
| CN113811529A (en) | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | Fibroblast activation protein inhibitor |
| EP4019507A1 (en) | 2020-02-12 | 2022-06-29 | Philochem AG | Fibroblast activation protein ligands for targeted delivery applications |
| BR112022016049A2 (en) * | 2020-02-12 | 2022-11-16 | Philochem Ag | FIBROBLAST ACTIVATION PROTEIN BINDERS FOR TARGETED RELEASE APPLICATIONS |
| WO2021234181A1 (en) * | 2020-05-22 | 2021-11-25 | Universität Heidelberg | Use of fap inhibitor in a method of diagnosis |
| CN111991570B (en) * | 2020-07-24 | 2021-05-18 | 北京大学 | FAP-alpha specific tumor diagnosis SPECT imaging agent |
| CN114073781A (en) * | 2020-08-11 | 2022-02-22 | 上海健康医学院 | Tumor interstitial developer and preparation method thereof |
| CN112138175A (en) * | 2020-09-01 | 2020-12-29 | 上海市质子重离子临床技术研发中心 | A radionuclide99mPreparation method of Tc-labeled FAPI (FAPI) |
| CN112972707A (en) * | 2020-09-10 | 2021-06-18 | 广州呼吸健康研究院 | 18F-FDG and68application of Ga-FAPI |
| CN112194651B (en) * | 2020-10-12 | 2021-11-09 | 南方医科大学南方医院 | Precursor compound of PET tracer and application thereof |
| CN114380795A (en) * | 2020-10-22 | 2022-04-22 | 四川大学华西医院 | Deuterated FAP inhibitor and application thereof |
| CN112023064A (en) * | 2020-11-03 | 2020-12-04 | 南京大为科创服务有限责任公司 | Tin-based derivative of fibroblast activation protein inhibitor for labeling nuclide 211At and preparation method and application thereof |
| CN112933253A (en) * | 2020-11-13 | 2021-06-11 | 上海市质子重离子临床技术研发中心 | Compound with radioactive nuclide labeled FAPI and synthesis process method thereof |
| CN112409414B (en) * | 2020-12-01 | 2021-10-26 | 北京师范大学 | Technetium-99 m labeled FAPI derivative containing isonitrile as well as preparation method and application thereof |
| AR124379A1 (en) | 2020-12-17 | 2023-03-22 | Astrazeneca Ab | N-(2-(4-CYANOTHIAZOLIDIN-3-IL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES |
| CN112522388A (en) * | 2020-12-18 | 2021-03-19 | 上海市东方医院（同济大学附属东方医院） | Application of fibroblast activation protein as drug target in treating osteoarthritis |
| CN114790194B (en) * | 2020-12-21 | 2024-03-26 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
| TW202241867A (en) * | 2020-12-21 | 2022-11-01 | 大陸商蘇州藥明博銳生物科技有限公司 | Fibroblast activating protein inhibitors |
| WO2022135325A1 (en) * | 2020-12-21 | 2022-06-30 | 苏州药明博锐生物科技有限公司 | Fibroblast activated protein inhibitor |
| CN117545481A (en) * | 2021-02-01 | 2024-02-09 | 五一一制药股份有限公司 | Radiolabeled ligand for fibroblast activation protein-alpha imaging agent and preparation method thereof |
| CN113582975A (en) * | 2021-07-03 | 2021-11-02 | 上海蓝纳成生物技术有限公司 | Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof |
| CN114369084B (en) * | 2021-02-10 | 2023-02-03 | 烟台蓝纳成生物技术有限公司 | Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof |
| CN117120428A (en) * | 2021-02-10 | 2023-11-24 | 烟台蓝纳成生物技术有限公司 | Truncated Evan blue modified fibroblast activation protein inhibitor and preparation method and application thereof |
| IL304960A (en) | 2021-02-12 | 2023-10-01 | Philochem Ag | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| EP4043452A1 (en) | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| BR112023020123A2 (en) * | 2021-04-02 | 2024-01-23 | Univ Johns Hopkins | HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGING ALPHA FIBROBLAST ACTIVATING PROTEIN AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| MX2021005089A (en) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiopharmaceuticals based on ((r)-1-((6-hydrazinilnicotinoyl) d-alanyl) pirrolidin-2-il)boronic acid (hynic-ifap) for detecting overexpression of the fibrolasts activation protein. |
| CN113292538A (en) * | 2021-05-10 | 2021-08-24 | 北京肿瘤医院(北京大学肿瘤医院) | Compound of targeting tumor-associated fibroblast activation protein, preparation method and application thereof, and tumor developer targeting FAP |
| CN113444146B (en) * | 2021-06-01 | 2022-03-11 | 南方医科大学南方医院 | Targeted fibroblast activation protein probe, preparation method and application thereof in preparation of PET (polyethylene terephthalate) imaging agent |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| CN113603678A (en) * | 2021-08-10 | 2021-11-05 | 上海蓝纳成生物技术有限公司 | Diagnosis medicine of target fibroblast activation protein and preparation method thereof |
| CN113621021A (en) * | 2021-08-10 | 2021-11-09 | 上海蓝纳成生物技术有限公司 | Therapeutic drug targeting fibroblast activation protein and preparation method thereof |
| TW202320805A (en) * | 2021-08-18 | 2023-06-01 | 美商杜夫特學院信託管理公司 | Radiofluorinated agents for pet imaging selectively targeting fibroblast activation protein |
| CN117460826A (en) * | 2021-09-14 | 2024-01-26 | 菲柏生物医学技术（广州）有限公司 | siRNA conjugate targeting FAP positive cells, and pharmaceutical composition and application thereof |
| CN113880810B (en) * | 2021-09-24 | 2023-02-28 | 厦门大学 | Nuclide-labeled complex and preparation method and application thereof |
| CN113880811B (en) * | 2021-09-29 | 2022-09-02 | 厦门大学附属第一医院 | FAPI dimer compound, FAPI dimer-based tumor diagnosis PET imaging agent, and preparation method and application thereof |
| CN114099717A (en) * | 2021-09-30 | 2022-03-01 | 同济大学 | Tumor fibroblast activation protein targeted magnetic resonance contrast agent and preparation and application thereof |
| AU2022358921A1 (en) | 2021-10-04 | 2024-05-02 | Philochem Ag | Radiolabelled fibroblast activation protein ligands |
| TW202317541A (en) | 2021-10-28 | 2023-05-01 | 行政院原子能委員會核能研究所 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof |
| CN114315795B (en) * | 2021-11-30 | 2023-05-02 | 北京师范大学 | 68 Ga-marked inhibitor radioactive probe for targeting fibroblast activation protein and preparation method thereof |
| DE102021133942A1 (en) | 2021-12-20 | 2023-06-22 | Atoms for Cure GmbH | FAP-addressing pharmaceutical for the therapy and diagnosis of cancer diseases |
| CN114573558B (en) * | 2022-01-05 | 2022-11-08 | 四川大学华西医院 | Water-soluble methyl benzyl ether derivative, positron nuclide probe, nuclide marker, preparation method and application |
| WO2023144379A1 (en) | 2022-01-30 | 2023-08-03 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
| WO2023162946A1 (en) * | 2022-02-22 | 2023-08-31 | 国立大学法人大阪大学 | RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF |
| TW202404950A (en) * | 2022-04-21 | 2024-02-01 | 大陸商上海先通生物科技有限公司 | Fap inhibitors |
| WO2023222558A1 (en) | 2022-05-14 | 2023-11-23 | Zounek Alexis Nikolai | Precursor and theranostic radiotracer with improved tumor retention |
| WO2023247489A1 (en) | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| CN115304582B (en) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-alpha specific tumor diagnostic imaging agent |
| WO2024022332A1 (en) | 2022-07-26 | 2024-02-01 | Shanghai Sinotau Biotech. Co., Ltd | Fap inhibitors |
| WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
| WO2024064969A2 (en) | 2022-09-23 | 2024-03-28 | Nuclidium Ag | High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
| WO2024064968A1 (en) | 2022-09-23 | 2024-03-28 | Nuclidium Ag | Fibroblast activation protein (fap) inhibitors, fap conjugates, and diagnostic and therapeutic uses thereof |
| CN115286697B (en) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | Dual-targeting compound and preparation method and application thereof |
| CN115505032A (en) * | 2022-09-29 | 2022-12-23 | 烟台蓝纳成生物技术有限公司 | Fibroblast activation protein FAP and integrin alpha v β 3 Dual-targeting compound and preparation method and application thereof |
| CN117883585A (en) * | 2022-10-14 | 2024-04-16 | 无锡诺宇医药科技有限公司 | Medicine for targeting fibroblast activation protein and application thereof |
| CN115838393B (en) * | 2023-02-16 | 2023-05-05 | 烟台蓝纳成生物技术有限公司 | Intermediate for FAPI synthesis and preparation method and application thereof |
| CN116874545B (en) * | 2023-09-07 | 2024-01-05 | 山东第一医科大学(山东省医学科学院) | Coupling medicine, preparation method thereof and application of coupling medicine in preparation of medicine for treating rheumatoid arthritis synovium |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| WO2007149456A2 (en) * | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| EP2397466B1 (en) * | 2010-06-15 | 2012-11-28 | Centre National De La Recherche Scientifique CNRS | X-ray and gamma-photon activatable organic compounds, their preparation and their uses |
| ES2929179T3 (en) * | 2011-08-30 | 2022-11-25 | Tufts College | FAP-activated proteasome inhibitors for the treatment of solid tumors |
| WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| PL3433238T3 (en) * | 2016-03-22 | 2021-12-13 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| WO2018111989A1 (en) * | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| MX2020004807A (en) * | 2017-10-23 | 2020-10-05 | Univ Johns Hopkins | Imaging and radiotherapeutics agents targeting fibroblast-activation protein-¿ (fap-¿). |
-
2019
- 2019-02-06 SG SG11202007180QA patent/SG11202007180QA/en unknown
- 2019-02-06 IL IL276594A patent/IL276594B2/en unknown
- 2019-02-06 BR BR112020015985-9A patent/BR112020015985A2/en unknown
- 2019-02-06 WO PCT/EP2019/052952 patent/WO2019154886A1/en active Application Filing
- 2019-02-06 CN CN201980010828.6A patent/CN111699181A/en active Pending
- 2019-02-06 JP JP2020563822A patent/JP2021512949A/en active Pending
- 2019-02-06 AU AU2019219057A patent/AU2019219057B2/en active Active
- 2019-02-06 MX MX2020008271A patent/MX2020008271A/en unknown
- 2019-02-06 CA CA3088326A patent/CA3088326A1/en active Pending
- 2019-02-06 US US16/964,302 patent/US20210038749A1/en not_active Abandoned
- 2019-02-06 KR KR1020207025535A patent/KR20200123148A/en not_active Application Discontinuation
- 2019-02-06 EP EP19703101.6A patent/EP3749663A1/en active Pending
-
2020
- 2020-08-03 CO CONC2020/0009625A patent/CO2020009625A2/en unknown
- 2020-08-04 CL CL2020002026A patent/CL2020002026A1/en unknown
-
2022
- 2022-07-01 US US17/810,370 patent/US20230112012A1/en active Pending
-
2023
- 2023-02-24 AU AU2023201120A patent/AU2023201120A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230112012A1 (en) | 2023-04-13 |
| AU2019219057A1 (en) | 2020-07-09 |
| CA3088326A1 (en) | 2019-08-15 |
| EP3749663A1 (en) | 2020-12-16 |
| CL2020002026A1 (en) | 2020-11-27 |
| CO2020009625A2 (en) | 2020-08-21 |
| IL276594B2 (en) | 2023-11-01 |
| RU2020126278A (en) | 2022-03-09 |
| IL276594A (en) | 2020-09-30 |
| CN111699181A (en) | 2020-09-22 |
| MX2020008271A (en) | 2020-11-09 |
| KR20200123148A (en) | 2020-10-28 |
| US20210038749A1 (en) | 2021-02-11 |
| BR112020015985A2 (en) | 2020-12-15 |
| WO2019154886A1 (en) | 2019-08-15 |
| IL276594B1 (en) | 2023-07-01 |
| AU2019219057B2 (en) | 2022-11-24 |
| RU2020126278A3 (en) | 2022-03-09 |
| JP2021512949A (en) | 2021-05-20 |
| AU2023201120A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276594A (en) | Fap inhibitor | |
| IL283639A (en) | Kif18a inhibitors | |
| ZAA201801350S (en) | Case | |
| ZAA201801147S (en) | Case | |
| ZA202006327B (en) | Magl inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201806130D0 (en) | Inhibitor compounds | |
| GB201806131D0 (en) | Inhibitor compounds | |
| GB201806132D0 (en) | Inhibitor coumpounds | |
| GB201914902D0 (en) | Ramp | |
| ZAA201801602S (en) | Pallets | |
| ZAA201801603S (en) | Pallets | |
| ZAA201801601S (en) | Pallets | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708999D0 (en) | Recrystallization Inhibitor | |
| GB201708510D0 (en) | Inhibitor compounds |